Cencora(NYSE) COR

Cencora, Inc. helps hospitals get the medicines they need. It ships drugs and vaccines to doctors across the globe. The company also supplies health products for pets and livestock.

The Business Units

• U.S. Healthcare Solutions: Distribution of brand-name and generic pharmaceuticals, including specialty treatments and weight loss drugs, to hospitals and retail pharmacies.
• International Healthcare Solutions: Global wholesale pharmaceutical distribution and commercialization services for healthcare providers and manufacturers in several countries.
• Specialty Logistics: Transportation and storage solutions for sensitive biopharmaceutical items like vaccines, blood derivatives, and clinical trial materials.
• Animal Health: Supply of pharmaceuticals, vaccines, and diagnostics for both companion and production animals; revenue reached $1.5 billion in the three months ended June 30, 2026.

Strategic Moves and Global Growth

• Acquired OneOncology in February 2026 to enhance specialty pharmaceutical services for physician practices.
• Purchased RCA in January 2025 to expand the company's healthcare solutions and services portfolio.
• Rebranded from AmerisourceBergen to Cencora in August 2023 to unify its global identity.
• Divested the U.S. Consulting Services business in April 2026 to focus on core operations.

Delivering Health Across Borders

Cencora manages a global network that delivers vital medicines to hospitals, pharmacies, and clinics. International operations accounted for approximately 10% of total revenue in the nine months ended June 30, 2026.

The Financial Scorecard

• Revenue reached $84.8 billion in the three months ended June 30, 2026, up 5.1% year over year.
• Gross profit hit $3.6 billion in the three months ended June 30, 2026, up 24.1% year over year.
• Operating income reached $1.1 billion in the three months ended June 30, 2026, up 29.1% year over year.
• Sales of weight loss and diabetes drugs in the GLP-1 class grew by $2.3 billion in the three months ended June 30, 2026.
• Cash generated from operations was $1.7 billion in the nine months ended June 30, 2026, up from $0.7 billion in the prior year period.

Bottom Line

Cencora has evolved from a domestic distributor into a global healthcare services provider through strategic acquisitions. This transition allows the company to manage high-growth specialty drugs and international pharmaceutical logistics.